Elicit: Efficacy of Oral Citicoline in Neuro-Inflammation

Efficacy of Oral Citicoline in Neuro-Inflammation

How effective is oral citicoline for neuro-inflammation?

Studies indicate oral citicoline (500-2000mg/day) improves recovery outcomes in neuro-inflammatory conditions with minimal side effects, particularly at higher doses.

Abstract

This report examined three studies investigating oral citicoline for neuro-inflammation: two meta-analyses of stroke treatments and one pilot study of non-arteritic ischemic optic neuropathy (NAION).

The included stroke meta-analyses reported that citicoline treatment within 24 hours of onset was associated with higher rates of complete recovery at 3 months compared to controls (25.2% vs 20.2%, OR 1.33, 95% CI 1.10-1.62). In the NAION pilot study, patients showed improvements in visual function parameters after 6 months of treatment, with effects continuing through a 3-month wash-out period.

Across the studies, dosages ranged from 500 to 2000 mg/day, with the stroke meta-analyses reporting greater effects at higher doses. Treatment periods varied from 6 weeks to 6 months. The included studies reported minimal adverse events with citicoline administration.

Several limitations affect interpretation of these findings: only three studies were included, they covered different neurological conditions, and full-text access was unavailable for two meta-analyses. Additional research appears needed to determine optimal dosing, treatment duration, and effectiveness across various neuro-inflammatory conditions.

Methods

We analyzed 3 sources from an initial pool of 96, using 7 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Papers identified with Elicit search

n = 96

Papers screened using: Population Type, Administration Route, Outcome Measures, Study Design, Intervention Isolation, Study Model, Administration Method

n = 96

Papers screened out

n = 93

Papers included for extraction

n = 3

Data extraction

Study Design:

Identify and record the specific type of study design.

Randomization Process:

Examine the methods section for details about randomization.

Participant Characteristics:

Total number of participants
Medical condition/diagnosis
Age range or mean age
Gender distribution
Inclusion and exclusion criteria

Citicoline Intervention:

Dosage (mg/day)
Route of administration
Duration of intervention
Frequency of administration

Primary Outcome Measures:

Specific measurement tools used
Time points of outcome assessment
Key results for each primary outcome

Safety and Adverse Events:

Reported adverse events
Mortality rates
Any significant safety findings

Results

Characteristics of Included Studies

Study	Full text retrieved	Study Design	Population Size	Treatment Protocol	Primary Outcomes
Dávalos et al., 2002	No	Meta-analysis of prospective, randomized, placebo-controlled, double-blind clinical trials	1372 patients with acute ischemic stroke	Oral citicoline (500, 1000, or 2000 mg/day) for at least 6 weeks	Combined eval using NIH Stroke Scale, modified Rankin Scale
EFSA NDA Panel, 2018	No	Meta-analysis of placebo-controlled, double-blind, randomized clinical trials	1372 subjects (789 citicoline, 583 placebo)	Oral citicoline (500, 1000, or 2000 mg/day) for at least 6 weeks	Efficacy endpoints using Barthel index, NIHSS
Parisi et al., 2019	Yes	Randomized, monocentric, prospective, operator-masked pilot study	36 patients with NAION and 20 age-matched controls	500 mg/day of oral citicoline solution for 6 months, followed by 3-month wash-out	Visual Acuity, Pattern Electroretinogram, Visual Evoked Potentials

Effects

Clinical Effectiveness

Study	Dosage Level	Treatment Duration	Efficacy Measures	Safety Profile
Dávalos et al., 2002	500, 1000, 2000 mg/day	At least 6 weeks	25.2% recovery in citicoline-treated patients vs 20.2% in placebo (OR 1.33, 95% CI 1.10-1.62)	Overall safety similar to placebo
EFSA NDA Panel, 2018	500, 1000, 2000 mg/day	At least 6 weeks	Not specified in abstract	No significant differences in mortality
Parisi et al., 2019	500 mg/day	6 months	Significant improvements in Visual Acuity, Pattern Electroretinogram, etc. (p<0.01)	No adverse side effects reported

Treatment Timing and Duration

Study	Administration Timing	Duration of Treatment	Follow-up Period	Observed Effects
Dávalos et al., 2002	Within 24 hours of stroke onset	At least 6 weeks	3 months	Increased probability of complete recovery
EFSA NDA Panel, 2018	Not specified	At least 6 weeks	3 months	Not specified in abstract
Parisi et al., 2019	Not specified for NAION onset	6 months	9 months	Significant improvements in visual function

References

Parisi et al., 2019 - Neuroenhancement and neuroprotection by oral solution citicoline.
Dávalos et al., 2002 - Oral Citicoline in Acute Ischemic Stroke.
EFSA NDA Panel, 2018 - Scientific on the safety of citicoline.